Results 201 to 210 of about 7,770,494 (359)
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Jens G. Lohr +20 more
semanticscholar +1 more source
Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici +8 more
wiley +1 more source
857. Genetic Mapping of the Humeral Immune Response to Adenovirus Gene Therapy [PDF]
openalex +1 more source
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert +13 more
wiley +1 more source
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.
Megan D Hoban, S. Orkin, D. E. Bauer
semanticscholar +1 more source
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf +10 more
wiley +1 more source
Genetic heterogeneity in response to adenovirus gene therapy. [PDF]
Pierre Lefesvre +4 more
openalex +1 more source
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
C. Ng +17 more
semanticscholar +1 more source
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser +14 more
wiley +1 more source

